Literature DB >> 24945339

The combined treatment of venlafaxine and ECT in treatment-resistant depressive patients.

Nesrin Dilbaz1, Cem Sengül, Tuncer Okay, Göksel Bayam, Ali Türkoglu.   

Abstract

Objective To evaluate the efficacy and safety of the combination treatment of ECT and venlafaxine among treatment-resistant depressive patients. Methods We reviewed 21 depressive patients who were treated with a combination of electroconvulsive therapy (ECT) and venlafaxine. The indication of the ECT-venlafaxine treatment was inadequate response to at least one antidepressant trial of adequate doses and duration. Propofol was used as an anesthetic agent during ECT treatments. Results Ninety percent of the patients benefited from the combined treatment. The responsivity to the combination treatment was not associated with high dose of venlafaxine. In most of the patients, the combined treatment was safe and well tolerated. Adverse reactions occurred in 57% of the patients and included concentration difficulties (four patients), memory problems (seven patients) and headache (one patient). No asystole was observed. Treatment was safe with a low dose of venlafaxine equal to or lower than 225 mg/day. Conclusions It seems that treatment of ECT combined with low dose venlafaxine and propofol as anesthetic agent is effective and safe. This strategy may be a therapeutic option in treatment-resistant depressive patients.

Entities:  

Keywords:  ECT; propofol; treatment resistant depression; venlafaxine

Year:  2005        PMID: 24945339     DOI: 10.1080/13651500510018202

Source DB:  PubMed          Journal:  Int J Psychiatry Clin Pract        ISSN: 1365-1501            Impact factor:   1.812


  1 in total

1.  Practice of Acute and Maintenance Electroconvulsive Therapy in the Psychiatric Clinic of a University Hospital from Turkey: between 2007 and 2013.

Authors:  Melike Ceyhan Balci Sengul; Ayse Nur Inci Kenar; Ezgi Hanci; İbrahim Sendur; Cem Sengul; Hasan Herken
Journal:  Clin Psychopharmacol Neurosci       Date:  2016-02-29       Impact factor: 2.582

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.